在注射肉毒神经毒素A到马塞特肌肉后,部肌肉在补偿性地变厚
Xueyin Liao1, Shihong Zhang, Ruijia Dong
1Department of Plastic Surgery, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
The Journal of craniofacial surgery
|April 15, 2025
概括
毒素A注射到体肌肉中会导致肌肉缩,但是体肌肉通过加厚来补偿. 这项研究发现,在治疗后,masseter厚度显著下降,temporalis厚度相应增加.
科学领域:
- 人体解剖学 解剖学 解剖学
- 生理学 生理学 生理学
- 医疗成像医学成像
背景情况:
- 按摩器和肌是关键的肌,对和发言至关重要.
- 之前的研究表明,麻氏菌毒素A注射导致肌肉缩,而没有显著的障碍.
研究的目的:
- 为了检查是否时肌经历补偿性加厚后肉毒素A注射到按摩器肌肉.
主要方法:
- 这是一项前性研究,涉及10名接受毒素A注射到肌肌肉的患者.
- 超声波用于测量静止和收缩前和注射后12周的休息和收缩期间的masseter和temporalis肌肉厚度.
- 统计分析包括重复测量单向ANOVA和线性回归来评估变化和关系.
主要成果:
- 观察到masseter肌肉厚度的统计学上显著下降,同时在3个月内显著增加temporalis肌肉厚度.
- 按摩器厚度从14.21±2.95毫米减少到10.42±1.59毫米的静止状态 (P<0.0001).
- 骨的厚度从9.27±2.18毫米增加到13.05±1.49毫米休息 (P<0.0001),在收缩状态中也有类似的显著变化. 在两个肌肉的厚度之间发现了负线性关系.
结论:
- 毒素注射到肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉肌肉
- 肌肌肉表现出补偿性加厚,以应对肌肉缩.
- 这种补偿机制似乎有效,没有报告严重并发症.
相关概念视频
Muscles for Facial Expressions
1.7K
The craniofacial muscles are a collection of approximately 20 thin skeletal muscles situated beneath the skin of the face and scalp. These muscles, primarily responsible for the vast array of human facial expressions, originate from the bones or fibrous structures of the skull and extend outwards to connect with the skin. While most skeletal muscles in the body are enveloped in thick fascia, facial muscles generally have a more delicate fascial covering, with the buccinator muscle being a...
1.7K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
629
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
629
Myasthenia Gravis: Overview and Treatment
980
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
980
Skeletal Muscle Relaxants: Therapeutic Uses
441
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
441
Myasthenia Gravis: Diagnostic Tests
554
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
554
Disorders of the Skeletal Muscle
829
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
829


